Regeneron, Lilly grapple with clinical endpoints as obesity space moves to improving weight loss

The next frontier for pharma in the obesity space is improving the quality of weight loss. The approved GLP-1 medicines, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, are known to cause lean muscle loss as well as the overall weight loss patients are looking for.

But as potential combo drugs inch closer to phase 3, what exactly will the FDA be looking for in terms of a clinical endpoint?